Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727182 | 0.91 | ALDH1A1 (0.37) | KDM4EALDH1A1CYP1A2HPGDGAA | |
| SCHEMBL6450955 | 0.90 | KDM4E (0.34) | KDM4EALDH1A1CYP1A2HPGDGAA | |
| SCHEMBL2691587 | 0.90 | RET (0.36) | KDM4EALDH1A1CYP1A2HPGDGAA | |
| SCHEMBL13186430 | 0.87 | KDM4E (0.39) | KDM4EALDH1A1CYP1A2HPGDGAA | |
| SCHEMBL2691323 | 0.86 | CA2 (0.38) | KDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL2692862 | 0.84 | CYP3A4 (0.45) | KDM4EALDH1A1HPGD | |
| SCHEMBL6444232 | 0.81 | NPC1 (0.34) | KDM4EALDH1A1CYP1A2HPGDGAA | |
| SCHEMBL13186528 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1CYP1A2HPGDGAA | |
| SCHEMBL13186529 | 0.76 | KDM4E (0.39) | KDM4EALDH1A1CYP1A2HPGDGAA | |
| SCHEMBL13186530 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1CYP1A2HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168792-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100226879-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ABBOT SARAH C | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226879-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, IFNAR1, RRM2B | KDM4E 2588/4885ALDH1A1 859/4885CYP1A2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.